Navigation Links
Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment

OAKLAND, Calif., Dec. 20 /PRNewswire/ -- The largest study to examine the effect of depression on HIV treatment found that depression significantly worsens a patient's adherence to highly active antiretroviral therapy and clinical measures, but that effective antidepressant medication can reverse this outcome, according to a study by the Kaiser Permanente Division of Research and the Group Health Cooperative published in the current online issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).

The study looked at 3,359 HIV-infected patients from seven Kaiser Permanente regions nationwide and Group Health in 2000 to 2003 to measure the effects of depression -- with and without selective serotonin reuptake inhibitors (SSRI) use -- on adherence and changes in viral and immunologic control in patients starting a new highly active antiretroviral therapy (HAART) regimen.

The researchers studied the patients' HAART adherence, viral loads, and changes in CD4 T-cell counts over a 12-month period. The study found that depressed patients -- 42 percent of the patient group -- had a lower adherence rate and worse viral therapy response compared to non-depressed patients. But depressed patients who were prescribed SSRI medication and adhered to it had the same outcomes as non-depressed patients.

"The take-home point of this study is that depression carries a worse prognosis for HAART in HIV patients. However, we also found that SSRIs can reverse this and improve outcomes for HIV-depressed patients," said Michael A. Horberg, MD, MAS, FACP, Director of HIV/AIDS for Kaiser Permanente and the lead author on the study. "HIV and depression often go hand in hand. If you are HIV-infected, you should be screened regularly for depression, and if you are depressed and you are going to go on HAART, it's very worthwhile to treat your depression."

Kaiser Permanente and Group Health are the second largest provider of HIV care in the United States, caring for more than 17,000 patients annually. Recent quality performance analysis show that Kaiser Permanente and Group Health HIV patients have a very high rate of adhering to their medicine, strong viral control and good responses to therapy.

Co-authors on the study included Kaiser Permanente's Michael Silverberg, PhD, MPH, Leo Hurley, MPH, William Towner, MD, Daniel Klein, MD, Susan Bersoff-Matcha, MD, Winkler Weinberg, MD, Diana Antoniskis, MD, Miguel Mogyoros, MD, Robert Dobrinich, MD, Charles Quesenberry, PhD, and Drew Anthony Kovach, MD, and Wayne Dodge, MD, of Group Health.

About Kaiser Permanente

Kaiser Permanente is America's leading integrated health plan. Founded in 1945, it is a not-for-profit; group practice program headquartered in Oakland, Calif. Kaiser Permanente serves 8.7 million members in nine states and the District of Columbia. Today it encompasses the not-for-profit Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and their subsidiaries, and the for-profit Permanente Medical Groups. Nationwide, Kaiser Permanente includes approximately 156,000 technical, administrative and clerical employees and caregivers, and 13,000 physicians representing all specialties. For more information about Kaiser Permanente, visit the Kaiser Permanente News Center at:

About the Kaiser Permanente Division of Research

The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the determinants of illness and well being and to improve the quality and cost-effectiveness of health care. Currently, the center's 400-plus staff is working on more than 250 epidemiological and health services research projects.

SOURCE Kaiser Permanente
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 North ... and is expected to grow at a CAGR of 7.6% from ... was valued at USD 135.6 million in 2014, and is expected ... --> According to the new Market Research Report "North ... non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis And ...
(Date:11/30/2015)... -- (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , ... 421,979 , 384,242 , 9.8 ... , (18.3) Medical Insurance Administration Service Income , ... Medical Devices and Accessories Sales , 89,645 , ... , 2,822 , 2,917 , ...
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... Products, Inc today announced the introduction of three Nightstick® brand LED traffic wands with an ... red ( NSP-1632 ), yellow ( NSP-1634 ) and blue ( NSP-1636 ), the SL-1600 ... 27 hours in blinking strobe mode using a fresh set of 3 AAA cells (included). ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, ... ... beauty are available today from the new company, Sublime Beauty NATURALS®. All products ... organic and natural products, like essential oils, organic facial serums and USDA Certified ...
(Date:11/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... November 29, 2015 ... ... child's football games, basketball games. Things that as a Mother and Wife would love ... it was no mistake that I just happened to call Dr. Zaidan first. They ...
(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... reality in the future. , It’s the future because flying cars are about to ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable help with ... to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a way to ... the benefits of a standard walker to improve the user’s quality of life. To ...
Breaking Medicine News(10 mins):